Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.41 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.40 |
| ▸ | BAZ2A | Q9UIF9 | 2/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17806584 | 0.82 | LRRK2 (0.41) | USP30BRD4CREBBPBAZ2BBAZ2A | |
| SCHEMBL19628541 | 0.82 | USP30 (0.42) | USP30BRD4CREBBPBAZ2BBAZ2A | |
| SCHEMBL19538863 | 0.82 | BRD4 (0.47) | USP30BRD4CREBBPBAZ2BBAZ2A | |
| SCHEMBL17809696 | 0.82 | ALOX5AP (0.44) | BRD4CREBBPLRRK2 | |
| SCHEMBL19175599 | 0.80 | LRRK2 (0.43) | USP30RETCNR1CNR2PIK3CD | |
| SCHEMBL19663510 | 0.80 | USP30 (0.40) | USP30RETCNR1CNR2LRRK2 | |
| SCHEMBL19531703 | 0.79 | LRRK2 (0.48) | USP30BRD4CREBBPCNR1CNR2 | |
| SCHEMBL17795290 | 0.79 | USP30 (0.39) | USP30BAZ2BBAZ2AGRM4RET | |
| SCHEMBL17809819 | 0.79 | ALOX5AP (0.44) | BRD4CREBBPLRRK2 | |
| SCHEMBL23761239 | 0.78 | PIK3CD (0.47) | USP30RETCNR1CNR2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| WO-2016086200-A9 | 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | USP30 2156/4885BRD4 11/4885CREBBP 6/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | USP30 2156/4885BRD4 11/4885CREBBP 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.